Jia-Jia Huang | Medical Oncology | Sun Yat-sen University Cancer Center-Sun Yat-sen University Cancer Center

Name: Jia-Jia Huang

Title: Attending Physician

Email:

Phone:

Profile

Dr. Huang received her Bachelor Degree from Sun Yat-sen University in 2005 and her Doctoral Degree in oncology from Sun Yat-sen University in 2008. In 2011 Dr. Huang completed three-year residency training of medical oncology. Now she is the physician-in-charge of medical oncology. From January of 2012 she went to IOSI as a visiting scholar for six months.

Interests

1. Schedule-dependent synergistic effect of targeting mTOR/Beclin 1 mediated autophagy-dependent senescence in the combination with chemotherapy for patients of NHL. National Natural Science Funds for Distinguished Young Scholar. 2014-2016. Principal Investigator

2. Mechanism of targeting mTOR mediated autophagy-dependent senescence in lymphoma. Guangdong Natural Science Foundation. 2013-2015. Principal Investigator

Education

Major: Medical Oncology and development of new anti-cancer drugs

Publications

1.Huang JJ, Li YJ, Xia Y, Wang Y, WeiWX, Zhu YJ, Lin TY, Huang HQ, Jiang WQ, Li ZM.Prognostic significance of peripheral monocyte count in patients withextranodal natural killer/T-cell lymphoma.BMC Cancer. 2013 May 3;13:222.

2.Huang JJ, ZhuYJ, Xia Y, Zhao W, Lin TY, Jiang WQ, Huang HQ, Li ZM.A novel prognostic model for extranodal natural killer/T-cell lymphoma.Med Oncol. 2012Sep;29(3):2183-90.

3.Li ZM,Huang JJ,Xia Y,Sun J,Huang Y,Wang Y,Zhu YJ,Li YJ,Zhao W,Wei WX,Lin TY,Huang HQ,Jiang WQ. Blood lymphocyte-to-monocyte ratio identifies high-riskpatients in diffuse large B-cell lymphoma treated with R-CHOP.PLoS One.2012;7(7):e41658.

4.Li ZM,Huang JJ,Xia Y,Zhu YJ,Zhao W,Wei WX,Jiang WQ,Lin TY,Huang HQ,Guan ZZ. High Ki-67 expression in diffuse large B-cell lymphomapatients with non-germinal center subtype indicates limited survival benefitfrom R-CHOP therapy.Eur J Haematol.2012 Jun;88(6):510-7.

5. Huang JJ, Li ZM, Huang Y, Huang Y,Tian Y, He XX, Xiao J, Lin TY.Schedule-dependent inhibition of T-cell lymphoma cells by cotreatmentwith the mTOR inhibitor everolimus and anticancer drugs.Invest New Drugs. 2012 Feb;30(1):223-35.

6. Huang JJ, Zhu YJ, Lin TY, Jiang WQ,Huang HQ, Li ZM.Beclin 1 expression predicts favorable clinical outcome in patients withdiffuse large B-cell lymphoma treated with R-CHOP.Hum Pathol. 2011Oct;42(10):1459-66.

7.Zhu YJ,Huang JJ,Xia Y,Zhao W,Jiang WQ,Lin TY,Huang HQ,Li ZM. Primary mediastinal large B-cell lymphoma (PMLBCL) inChinese patients: clinical characteristics and prognostic factors.Int J Hematol.2011 Aug;94(2):178-84.

8. Huang JJ, Jiang WQ, Lin TY, Huang Y,Xu RH, Huang HQ, Li ZM.Absolute lymphocyte count is a novel prognostic indicator in extranodalnatural killer/T-cell lymphoma, nasal type.Ann Oncol. 2011 Jan;22(1):149-55.

9. Huang JJ, Li HR, Huang Y, Jiang WQ, XuRH, Huang HQ, Lv Y, Xia ZJ, Zhu XF, Lin TY, Li ZM.Beclin 1 expression: a predictor of prognosis in patients with extranodalnatural killer T-cell lymphoma, nasal type.Autophagy. 2010 Aug;6(6):777-83.

10. Huang JJ, Cai MY, Ye S, Li ZM, HuangHQ, Lin TY.Clinical analysis of 19 cases of subcutaneous panniculitis T-celllymphoma with literature review.Ai Zheng. 2009 Oct;28(10):1093-9.

11. Huang JJ, Lin TY.mTOR signal pathway and itsinhibitors in antitumor therapy: a review.Ai Zheng. 2007 Dec;26(12):1397-403.

Updated by International Office, Sun Yat-sen University Cancer Center

Our Experts